Research Summary
Analyzed using Evidence Intelligence™

Caloric restriction improves glycemic control

Last updated August 24, 2026

Key finding

TIR improved from 84.3% to 90.3% (P = 0.041)

This study investigated the effects of caloric restriction on glycemic control in adults with type 2 diabetes and obesity, finding significant improvements in several key metrics.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Save research, organize studies, and quickly find important evidence again.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

This study investigated the effects of caloric restriction on glycemic control in adults with type 2 diabetes and obesity, finding significant improvements in several key metrics.

Clinical relevance

These findings are clinically significant as they suggest that caloric restriction can be an effective strategy for improving glycemic control in individuals with type 2 diabetes and obesity. This approach may help reduce the risk of diabetes-related complications and improve overall health outcomes.

Keep in mind

The study had a single-arm design, limiting comparisons. Changes in C-peptide index were not significant, indicating potential measurement limitations. The generalizability of findings may be limited to similar populations.

Published in

Journal Reference

Publication details and source links for this paper.

Jinyoung K, Joonyub L, Mee KK, et al. Caloric restriction improves glycemic control in adults with type 2 diabetes and obesity. Journal of Diabetes Investigation. 2026;17(7):1106-1114. doi:10.1111/jdi.70308

Main Effects

Time in range (TIR) improved from 84.3% to 90.3% (P = 0.041)

BMI decreased from 29.3 to 26.7 kg/m² (P < 0.001)

Fasting plasma glucose (FPG) decreased from 127.8 mg/dL to 110.2 mg/dL (P < 0.001)

Glycemic variability (CV) decreased significantly (P < 0.001)

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Continuous glucose monitoring and 2-hour plasma glucose, BMI, C-peptide index (CPI), and 7 more.

Primary intervention

Continuous glucose monitoring

Primary outcomes

  • 2-hour plasma glucose
  • BMI
  • C-peptide index (CPI)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

10
Evidence pairs
10
Relationships
4
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

4

Related topics

10

Evidence pairs

862

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 10 evidence relationships
  • Includes primary outcome data
  • Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Add related evidence to your Evidence Tracker

Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Primary evidence

Evidence relationship

Insulin Delivery Systems and CGM Time in Range

Related evidence

Evidence relationship

Insulin Delivery Systems and Fasting Glucose

Save evidence

Evidence relationship

Insulin Delivery Systems and Postprandial and OGTT Glucose

Save evidence

Core evidence

Study findings

The primary outcomes reported in this study.

2-hour plasma glucose

Continuous glucose monitoring → 2-hour plasma glucose

Continuous glucose monitoring → 2-hour plasma glucose

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

BMI

Continuous glucose monitoring → BMI

Continuous glucose monitoring → BMI

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
75
Positive
ConsistencyScore™
35
mixed
Supporting studies: Based on 2 studies
Add to Evidence Tracker

C-peptide index (CPI)

Continuous glucose monitoring → C-peptide index (CPI)

Continuous glucose monitoring → C-peptide index (CPI)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
50
Neutral
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Continuous glucose monitoring → Fasting Plasma Glucose (FPG)

Continuous glucose monitoring → Fasting Plasma Glucose (FPG)

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
75
Positive
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Indices of 24-hour glycemic variability

Continuous glucose monitoring → Indices of 24-hour glycemic variability

Continuous glucose monitoring → Indices of 24-hour glycemic variability

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Matsuda index improvement

Continuous glucose monitoring → Matsuda index improvement

Continuous glucose monitoring → Matsuda index improvement

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Mean glucose levels measured during the intervention

Continuous glucose monitoring → Mean glucose levels measured during the intervention

Continuous glucose monitoring → Mean glucose levels measured during the intervention

Evidence Intelligence™
EvidenceScore™
Moderate
Score 69 · Based on 2 studies
ImpactScore™
50
Neutral
ConsistencyScore™
100
consistent
Supporting studies: Based on 2 studies
Add to Evidence Tracker

Time above range

Continuous glucose monitoring → Time above range

Continuous glucose monitoring → Time above range

Evidence Intelligence™
EvidenceScore™
79
Strong
ImpactScore™
56
Slightly Positive
ConsistencyScore™
35
mixed
Supporting studies: Based on 4 studies
Add to Evidence Tracker

Time below range

Continuous glucose monitoring → Time below range

Continuous glucose monitoring → Time below range

Evidence Intelligence™
EvidenceScore™
Strong
Score 79 · Based on 4 studies
ImpactScore™
63
Slightly Positive
ConsistencyScore™
75
consistent
Supporting studies: Based on 4 studies
Add to Evidence Tracker

Time in range

Continuous glucose monitoring → Time in range

Continuous glucose monitoring → Time in range

Evidence Intelligence™
EvidenceScore™
86
Strong
ImpactScore™
81
Positive
ConsistencyScore™
75
consistent
Supporting studies: Based on 8 studies
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

Evidence Suggest

  • TIR increased by 6% (P = 0.041), indicating better glucose control.
  • BMI decreased by 2.6 kg/m² (P < 0.001), reflecting weight loss.
  • FPG decreased by 17.6 mg/dL (P < 0.001), showing improved fasting glucose levels.
who this applies

Who this applies to

  • Adults aged 18-65 with type 2 diabetes
  • Individuals classified as obese with a BMI over 30 kg/m²
keep in mind

Keep in Mind

  • The study's single-arm design may limit the robustness of conclusions.
  • Results may not be applicable to populations outside the study criteria.
  • Further research is needed to confirm long-term effects of caloric restriction.
between the lines

Between the Lines

  • The study had a single-arm design, limiting comparisons.
  • Changes in C-peptide index were not significant, indicating potential measurement limitations.
  • The generalizability of findings may be limited to similar populations.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on Insulin Delivery Systems and CGM Time in Range, Insulin Delivery Systems and CGM Time in Range.

Related evidence relationships

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Insulin Delivery Systems improve cgm time in range?

Strong Evidence

Insulin Delivery Systems may improve CGM Time in Range.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    Time in range

    EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 1 study

  2. 2

    Time below range

    EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Consistent | 1 study

  3. 3

    Time above range

    EvidenceScore™ Strong | EvidenceScore™ 78.8 | weak positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
27 supporting studiesUpdated: Aug 2026

Does Insulin Delivery Systems improve fasting glucose?

Strong Evidence

Insulin Delivery Systems may improve Fasting Glucose.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Fasting Plasma Glucose (FPG)

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
6 supporting studiesUpdated: Aug 2026

Does Insulin Delivery Systems improve postprandial and ogtt glucose?

Strong Evidence

Insulin Delivery Systems may improve Postprandial and OGTT Glucose.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    2-hour plasma glucose

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Population details are unavailable.
3 supporting studiesUpdated: Aug 2026

Does Insulin Delivery Systems affect body mass index?

Moderate Evidence

Insulin Delivery Systems may improve Body Mass Index.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The available evidence reports mixed findings.

Ranked evidence signals

  1. 1

    BMI

    EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

  • Only a small number of supporting studies are available.
  • Population details are unavailable.
2 supporting studiesUpdated: Aug 2026
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.